Public Health · Vol. 11, No. 1 · 2026 · pp. 264–296 · e-ISSN 2472-3878

Host miRNA-Mediated Lineage Control and HPV Transcriptional Regulation: Mechanistic Insights with Environmental Sustainability Perspectives

Nishant Kumar Singh, Agrika Gupta, Aashi Saldhi, Arushi Chowdhary, Prankur Awasthi, Saba Hasan

DOI: https://doi.org/10.17140/phoj.2026.v11.i01.pp264-296.2597 · Published 2026-04-02 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2026 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Viruses cause 10%–15% of human cancers worldwide. Genomic instability, including DNA damage and the accumulation of mutations and aberrations, is the most common outcome of virus-induced reprogramming. One of the most infectious viruses that causes cancer and spreads sexually is the human papillomavirus (HPV). Mostly HPV causes tumours of the cervix, head and neck, anus, penis, vulva, and vagina. Most HPV infections go away within the first two years. However, in some instances, the infection persists, and the lesions develop into cancerous cells. The E7 and E6 oncoproteins are required for cancer development in high-risk HPV (HR-HPV) types, particularly HPV 18 and HPV 16. Noncoding microRNAs (miRNAs) are involved in post-transcriptional regulation in cervical cancer, as they are in other tumours, resulting in abnormal expression profiles. The miRNAs are small, non-coding, single-stranded post-transcriptional units that play a significant role in the mentioned tumours as tumour suppressors and oncogenes. However, the systemic impact of HPV16 on miRNAs is still unknown. These interactions map potential pathways, allowing possible mechanistic links to be identified. Further, we have discussed the prophylactic vaccines, which are currently in use as a preventive measure, and various therapeutic vaccines are still being developed and under clinical trials. The review paper highlights the functions of various miRNAs in HPV-induced cancers, along with HPV epidemiology, genome structure, stages of pathogenesis, the role of miRNAs in cancers, and recent advances made in the field of therapeutics.

Keywords: HPV; HR-HPV; HPV 16; miRNAs; cancers; expression; HPV16

Acknowledgement

• RegulatingpollutantsknowntodisruptmiRNA expression • Monitoring population miRNA signatures in pollutedregions • Developingenvironmentalstrategiesinformed bymolecularepidemiology • Using sustainability metrics to reduce exposure-drivencarcinogenesis.

9.Conclusion

In conclusion, the comprehensive understanding of HPV and its association with various cancers, alongwiththedevelopmentofeffectivetherapeutic strategies, sheds light on the advances being made in cancer research and treatment. The discussioncoveredtheepidemiologyofHPV-induced cancers, including cervical, head and neck, vaginal, anal, penile, and vulvar cancers, highlighting the role of microRNAs in cancer pathogenesis. The explorationalsodelvesintotheHPVgenome,stagesof pathogenesis,andvarioustherapeuticinterventions, Allauthorsdeclarethatthereisnoacknowledgement ofthismanuscript.

References

  1. HanahanD(2022)HallmarksofCancer:New Dimensions. CancerDiscovery 12:31–46. https://doi.org/10.1158/2159-8290.CD-21-1059 https://doi.org/10.1158/2159-8290.cd-21-1059
  2. MorandGB,CardonaI,CruzSBSC,etal(2022) TherapeuticVaccinesforHPV-Associated OropharyngealandCervicalCancer. IntJMolSci 23:8395. https://doi.org/10.3390/IJMS23158395 https://doi.org/10.3390/ijms23158395
  3. ShiadehAE,SofianiVH,AmoliSS,etal(2023) EBVandHPVInfectionsinColorectalCancerand TheirEffectonP53andP16ProteinExpression. IntJMolCellMed 12:288. https://doi.org/10.22088/IJMCM.BUMS.12.3.288 https://doi.org/10.22088/ijmcm.bums.12.3.288
  4. SzymonowiczKA,ChenJ(2020)Biologicaland clinicalaspectsofHPV-relatedcancers. Cancer BiolMed 17:864–878. https://doi.org/10.2 0892/J.ISSN.2095-3941.2020.0370
  5. RachmadPutraGofurN,RachmadaniPutri GofurA,NurRachmanPutraGofurR,etal(2022) ReviewArticle. JPharmaResDev 3(1):1–4
  6. LiY,XuC(2017)HumanPapillomavirus-Related Cancers. AdvExpMedBiol 1018:23–34. https://doi.org/10.1007/978-981-10-5765-63 https://doi.org/10.1007/978-981-10-5765-63
  7. MalikS,SahR,MuhammadK,WaheedY(2023) TrackingHPVInfectionandCancer Development. Vaccines 11:102. https://doi.org/10.3390/VACCINES11010102 https://doi.org/10.3390/vaccines11010102
  8. WildCP,WeiderpassE,StewartBW(2020) World CancerReport
  9. AzumaY,Kusumoto-MatsuoR,TakeuchiF,etal (2014)HPVGenotypeDistribution. JpnJClin Oncol 44:910–917. https://doi.org/10.1093/JJCO/HYU112 https://doi.org/10.1093/jjco/hyu112
  10. StarrettG,ChatterjeeS,StarrettGJ(2024) Microhomology-mediatedrepairandHPV oncogenesis. AuthoreaPreprints. https://doi. org/10.22541/AU.171006332.24357508/V1 https://doi.org/10.22541/au.171006332.24357508/v1
  11. KukimotoI(2024)RecentTopicsofHPVand CervicalCancer.3–21. https://doi.org/10.1007/978-981-99-9396-31 https://doi.org/10.1007/978-981-99-9396-31
  12. RabiuI,YahuzaZ(2023)KnowledgeandAttitude towardsHPV. AdvVirol 2023:2803420. https://doi.org/10.1155/2023/2803420 https://doi.org/10.1155/2023/2803420
  13. CiotiA-M,StanescuAA,GrajdeanuIV,etal(2019) ClinicalManifestationsandBurdenofHPV Infection. ArchBalkMedUnion. https://doi.org/10.31688/ABMU.2019.54.4.19 https://doi.org/10.31688/abmu.2019.54.4.19
  14. SukR,LiaoK,BauerCX,etal(2022)HPVVaccine AdministrationTrends. JAMAHealthForum 3:e224716. https://doi.org/10.1001/JAMA HEALTHFORUM.2022.4716 https://doi.org/10.1001/jama
  15. RaoS,GurenMG,KhanK,etal(2021)Anal cancerguidelines. AnnOncol 32:1087–1100. https://doi.org/10.1016/J.ANNONC.2021.06.015 https://doi.org/10.1016/j.annonc.2021.06.015
  16. LohHY,NormanBP,LaiKS,etal(2019) MicroRNAsinBreastCancer. IntJMolSci 20:4940. https://doi.org/10.3390/IJMS20194940 https://doi.org/10.3390/ijms20194940
  17. OlesenTB,SandFL,RasmussenCL,etal(2019) HPVDNAinpenilecancer. LancetOncol 20:145–158. https://doi.org/10.1016/S1470-2045(18)30682-X https://doi.org/10.1016/s1470-2045(18)30682-x
  18. RosenbergAJ,VokesEE(2021)Treatment De-escalationinHeadandNeckCancer. Oncologist 26:40–48. https://doi.org/10.1 634/THEONCOLOGIST.2020-0303
  19. BaralSK,BiswasP,KaiumMA,etal(2022) VaginalCancermechanisms. FrontOncol 12:883805. https://doi.org/10.3389/FONC.2022.883805 https://doi.org/10.3389/fonc.2022.883805
  20. GuerendiainD,GrigorescuR,KirkA,etal(2022) HPVstatusinanalcancer. CancerMed 11:4193–4203. https://doi.org/10.1002/CAM4.4771 https://doi.org/10.1002/cam4.4771
  21. KostovS,DzhenkovD,MetodievD,etal(2021) HPVinfectionandvulvarcancer. GynecolOncol Rep 36:100760. https://doi.org/10.1016/J.GORE.2021.100760 https://doi.org/10.1016/j.gore.2021.100760
  22. FuL,TianT,YaoK,etal(2022)PenileCancer Incidencetrends. JMIRPublicHealthSurveill 8:e34874.https://doi.org/10.2196/34874 https://doi.org/10.2196/34874
  23. AlkhatibAJ,AlqararAAM(2023)Pathologyof HPV. JPatholLabMed 1:1–6
  24. FischerM,GrossmannP,PadiM,DeCaprioJA (2016)Cellcyclegenenetworks. NucleicAcids Res 44:6070–6086. https://doi.org/10.1093/NAR/GKW523 https://doi.org/10.1093/nar/gkw523
  25. BurleyM,RobertsS,ParishJL(2020)Epigenetic regulationofHPVtranscription. Semin Immunopathol 42:159–171. https://doi.org/10.1007/S00281-019-00773-0 https://doi.org/10.1007/s00281-019-00773-0
  26. BhattacharjeeR,DasSS,BiswalSS,etal(2022) MechanisticroleofHPV-associatedearly proteinsincervicalcancer. CritRevOncol Hematol 174:103675. https://doi.org/10.1 016/J.CRITREVONC.2022.103675
  27. MaB,FangJ,LinW,etal(2019)Point-of-care diagnosisofHPVgenotypesusingrecombinase polymeraseamplification. AnalBioanalChem 411:7451–7460. https://doi.org/10.1007/S00216-019-02113-5 https://doi.org/10.1007/s00216-019-02113-5
  28. LeiJ(Yearnotspecified)Preventionand prognosisofcervicalcancer.Karolinska Institutet,Stockholm,Sweden
  29. BonabFR,BaghbanzadehA,GhaseminiaM,etal (2021)MolecularpathwaysinHPV-induced cervicalcancer. EXCLIJ 20:320. https://doi.org/10.17179/EXCLI2021-3365 https://doi.org/10.17179/excli2021-3365
  30. JainM,YadavD,JarouliyaU,etal(2023) HPV-associatedcarcinogenesismechanisms. Pathogens 12:1380. https://doi.org/10.3390/PATHOGENS12121380 https://doi.org/10.3390/pathogens12121380
  31. PereiraD,AlvesN,SousaÂ,ValenteJFA(2024) Metal-basedapproachesincervicalcancer. Drug DiscovToday 29:104073. https://doi.org/10.1016/J.DRUDIS.2024.104073 https://doi.org/10.1016/j.drudis.2024.104073
  32. MukherjeeAG,WanjariUR,GopalakrishnanAV, etal(2022)Molecularpathogenesisand therapeuticstrategiesofHPVinfection. Pathogens 12:25. https://doi.org/10.3390/PATHOGENS12010025 https://doi.org/10.3390/pathogens12010025
  33. WarowickaA,BroniarczykJ,WęglewskaM,etal (2022)RoleofYY1inHPVlifecycleandcervical cancer. IntJMolSci 23:3453. https://doi.org/10.3390/IJMS23073453 https://doi.org/10.3390/ijms23073453
  34. RevathideviS,MuruganAK,NakaokaH,etal (2021)APOBECincervicalcancerpathogenesis. CancerLett 496:104–116. https://doi.org/10.1016/J.CANLET.2020.10.004 https://doi.org/10.1016/j.canlet.2020.10.004
  35. MallickS,ChoiY,TaylorAM,CosperPF(2024) HPV-inducedchromosomalinstability. Viruses 16:501.https://doi.org/10.3390/V16040501 https://doi.org/10.3390/v16040501
  36. SasakiH,ZlatescuMC,BetenskyRA,etal(2001) PTENalterationsandprognosis. AmJPathol 159:359–367. https://doi.org/10.1016/S0002-9440(10)61702-6 https://doi.org/10.1016/s0002-9440(10)61702-6
  37. KorzeniewskiN,TreatB,DuensingS(2011) HPV-16E7andcentriolemultiplication. Mol Cancer 10:1–5. https://doi.org/10.1186/1476-4598-10-61 https://doi.org/10.1186/1476-4598-10-61
  38. HardingSM,BenciJL,IriantoJ,etal(2017)DNA damageandmitoticprogression. Nature 548:466–470. https://doi.org/10.1038/NATURE23470 https://doi.org/10.1038/nature23470
  39. BannisterAJ,KouzaridesT(2011)Chromatin regulationbyhistonemodifications. CellRes 21:381–395.https://doi.org/10.1038/cr.2011.22 https://doi.org/10.1038/cr.2011.22
  40. PentlandI,Campos-LeónK,CoticM,etal(2018) HPVgenomeloopingandoncogeneactivation. PLoSBiol 16:e2005752. https://doi.org/10.1371/JOURNAL.PBIO.2005752 https://doi.org/10.1371/journal.pbio.2005752
  41. LaursonJ,KhanS,ChungR,etal(2010) EpigeneticrepressionbyHPVE7. Carcinogenesis 31:918–926. https://doi.org/10.1093/CARCIN/BGQ027 https://doi.org/10.1093/carcin/bgq027
  42. ZhangB,LaribeeRN,KlemszMJ,RomanA (2004)HistoneacetylationbyHPVE7. Virology 329:189–198. https://doi.org/10.1016/J.VIROL.2004.08.009 https://doi.org/10.1016/j.virol.2004.08.009
  43. WarburtonA,RedmondCJ,DooleyKE,etal (2018)HPVintegrationandsuper-enhancer formation. PLoSGenet 14:e1007179. https://doi.org/10.1371/JOURNAL.PGEN.1007179 https://doi.org/10.1371/journal.pgen.1007179
  44. BarbosaMS,EdmondsC,FisherC,etal(1990) HPVE7domainsandRBbinding. EMBOJ 9:153–160. https://doi.org/10.1002/J.14 60-2075.1990.TB08091.X https://doi.org/10.1002/j.14
  45. AwasthiP,KumarD,HasanS(2024)Roleof 14-3-3proteinsindisease. FrontMolBiosci 11:1353828. https://doi.org/10.3389/FMOLB.2024.1353828 https://doi.org/10.3389/fmolb.2024.1353828
  46. BlackfordAN,JacksonSP(2017)DNAdamage responsepathways. MolCell 66:801–817. https://doi.org/10.1016/J.MOLCEL.2017.05.015 https://doi.org/10.1016/j.molcel.2017.05.015
  47. Fradet-TurcotteA,Bergeron-LabrecqueF,Moody CA,etal(2011)HPVE1helicaseandDNA damageresponse. JVirol 85:8996–9012. https://doi.org/10.1128/JVI.00542-11 https://doi.org/10.1128/jvi.00542-11
  48. KaminskiP,HongS,KonoT,etal(2021) Topoisomerase2β inHPVreplication. mBio 12:1–11. https://doi.org/10.1128/MBIO.00005-21 https://doi.org/10.1128/mbio.00005-21
  49. MoodyCA(2019)ReplicationstressinHPV pathogenesis. JVirol 93. https://doi.org/10.1128/JVI.01012-17 https://doi.org/10.1128/jvi.01012-17
  50. SotoDR,BartonC,MungerK, McLaughlin-DrubinME(2017)KDM6Aincervical carcinoma. PLoSPathog 13. https://doi.org/10.1371/JOURNAL.PPAT.1006661 https://doi.org/10.1371/journal.ppat.1006661
  51. WendelS,WallaceNA(2023)Interactionsamong HPVproteinsandhostDNArepairfactors. mSphere 8. https://doi.org/10.1128/MSPHERE.00427-23 https://doi.org/10.1128/msphere.00427-23
  52. HuC,BugbeeT,GamezM,WallaceNA(2020) HPV8E6attenuatesnon-homologousend joining. Cancers 12:2356. https://doi.org/10.3390/CANCERS12092356 https://doi.org/10.3390/cancers12092356
  53. YuanCH,FilippovaM,Duerksen-HughesP(2012) ModulationofapoptoticpathwaysbyHPV. Viruses 4:3831–3850. https://doi.org/10.3390/V4123831 https://doi.org/10.3390/v4123831
  54. AnsariT,BrimerN,VandePolSB(2012)HPV16 E6interactionwithp53. JVirol 86:11386–11391. https://doi.org/10.1128/JVI.01236-12 https://doi.org/10.1128/jvi.01236-12
  55. ChenJ,ZhaoK-N,LiR,etal(2014) PI3K/Akt/mTORpathwayactivation. CurrMed Chem 21:3070–3080. https://doi.org/10.2 174/0929867321666140414095605
  56. BaarsmaHA,KönigshoffM,GosensR(2013) WNTsignalingpathwaymechanisms. PharmacolTher 138:66–83. https://doi.org/10.1016/J.PHARMTHERA.2013.01.002 https://doi.org/10.1016/j.pharmthera.2013.01.002
  57. DaiY,WilsonG,HuangB,etal(2014)Jagged1 silencingincancer. CellDeathDis 5:e1170. https://doi.org/10.1038/CDDIS.2014.137 https://doi.org/10.1038/cddis.2014.137
  58. RubinSM(2013)Retinoblastomaprotein phosphorylation. TrendsBiochemSci 38:12–19. https://doi.org/10.1016/J.TIBS.2012.10.007 https://doi.org/10.1016/j.tibs.2012.10.007
  59. HannaGJ,KacewA,ChauNG,etal(2018)PI3K pathwayinHPVcancer. JCIInsight 3:e122799. https://doi.org/10.1172/JCI.INSIGHT.122799 https://doi.org/10.1172/jci.insight.122799
  60. StanleyM(2020)ImmuneresponsestoHPV.In: HumanPapillomavirus pp283–297. https://doi.org/10.1016/B978-0-12-814 457-2.00018-0 https://doi.org/10.1016/b978-0-12-814
  61. MiuraS,KawanaK,SchustDJ,etal(2010)CD1d downregulationbyHPVE5. JVirol 84:11614–11623. https://doi.org/10.1128/JVI.01053-10 https://doi.org/10.1128/jvi.01053-10
  62. AndersonLA,O’RorkeMA,WilsonR,etal(2016) HPVprevalenceincervicalcancer. JMedVirol 88:1262–1270. https://doi.org/10.1002/JMV.24447 https://doi.org/10.1002/jmv.24447
  63. SteinbachA,RiemerAB(2018)Immuneevasion byHPV. IntJCancer 142:224–229. https://doi.org/10.1002/IJC.31027 https://doi.org/10.1002/ijc.31027
  64. GhoreshiZAS,MolaeiHR,ArefiniaN(2023)DNA virusesinhumancancer. CancerInform 22:1. https://doi.org/10.1177/11769351231154186 https://doi.org/10.1177/11769351231154186
  65. FischerM(2017)Evaluationofp53targetgenes. Oncogene 36:3943–3956. https://doi.org/10.1038/onc.2016.502 https://doi.org/10.1038/onc.2016.502
  66. XuM,KatzenellenbogenRA,GrandoriC, GallowayDA(2010)HPV16E6andNFkB activation. JVirol 84:11461–11469. https://doi.org/10.1128/JVI.00538-10 https://doi.org/10.1128/jvi.00538-10
  67. AttwoollC,OddiS,CartwrightP,etal(2005) E2F6complexandproliferation. JBiolChem 280:1199–1208. https://doi.org/10.1074/JBC.M412509200 https://doi.org/10.1074/jbc.m412509200
  68. YeM,LiS,LuoP,etal(2022)Geneticvariationof HPV51genes. JMedVirol 94:2811–2823. https://doi.org/10.1002/JMV.27603 https://doi.org/10.1002/jmv.27603
  69. AkagiK,LiJ,BroutianTR,etal(2014)HPV integrationandgenomicinstability. GenomeRes 24:185–199. https://doi.org/10.1101/GR.164806.113 https://doi.org/10.1101/gr.164806.113
  70. AguayoF,Perez-DominguezF,OsorioJC,etal (2023)PI3K/AKT/mTORinHPV-drivencancer. Biology 12:672. https://doi.org/10.3390/BIOLOGY12050672 https://doi.org/10.3390/biology12050672
  71. StengleinMD,BurnsMB,LiM,etal(2010) APOBEC3proteinsandDNAclearance. Nat StructMolBiol 17:222–229. https://doi.org/10.1038/NSMB.1744 https://doi.org/10.1038/nsmb.1744
  72. WangZ,WakaeK,KitamuraK,etal(2014) APOBEC3hypermutationinHPV16. JVirol 88:1308–1317. https://doi.org/10.1128/JVI.03091-13 https://doi.org/10.1128/jvi.03091-13
  73. ChenL,QiuX,ZhangN,etal(2017)APOBECand cervicalcarcinogenesis. BiosciTrends 11:383–388. https://doi.org/10.5582/BST.2017.01103 https://doi.org/10.5582/bst.2017.01103
  74. SayyedAA,GondaliyaP,BhatP,etal(2021) miRNAsincancerdiagnostics. CurrPharmDes 28:471–487. https://doi.org/10.2174/1381 612827666211109113305 https://doi.org/10.2174/1381
  75. SnoekBC,BabionI,Koppers-LalicD,etal(2019) microRNAprocessinginHPVcancers. CurrOpin Virol 39:23–32. https://doi.org/10.1016/J.COVIRO.2019.07.002 https://doi.org/10.1016/j.coviro.2019.07.002
  76. ShahV,ShahJ(2020)Recenttrendsintargeting miRNAsforcancertherapy. JPharmPharmacol 72:1732–1749. https://doi.org/10.1111/JPHP.13351 https://doi.org/10.1111/jphp.13351
  77. ChoW,AroraS,ThayanithyV,etal(2019) CirculatingmicroRNAsincancer:potentialand challenges. FrontGenet 10:626. https://doi.org/10.3389/FGENE.2019.00626 https://doi.org/10.3389/fgene.2019.00626
  78. YiM,XuL,JiaoY,etal(2020)Roleof cancer-derivedmicroRNAsinimmuneescape. J HematolOncol 13:1–14. https://doi.org/10.1186/S13045-020-00848-8 https://doi.org/10.1186/s13045-020-00848-8
  79. TaufiqulArifKM,ElliotEK,HauptLM,GriffithsLR (2020)EpigeneticmiRNAregulationincancer. Cancers 12:2922. https://doi.org/10.3390/CANCERS12102922 https://doi.org/10.3390/cancers12102922
  80. FarihaA,HamiI,TonmoyMIQ,etal(2022)Cell cycle-associatedmiRNAsinlungcancer. Heliyon 8:e11081. https://doi.org/10.1016/J.HELIYON.2022.E11081 https://doi.org/10.1016/j.heliyon.2022.e11081
  81. GuzM,JeleniewiczW,CybulskiM(2022) miR-1290asoncogenicbiomarker. IntJMolSci 23:1234. https://doi.org/10.3390/IJMS23031234 https://doi.org/10.3390/ijms23031234
  82. YouneszadeN,MarjaniM,PeiCP(2023)Deep learningincervicalcancerdiagnosis. IEEE Access 11:6133–6149. https://doi.org/10.1109/ACCESS.2023.3235833 https://doi.org/10.1109/access.2023.3235833
  83. BalasubramaniamSD,BalakrishnanV,OonCE, KaurG(2019)Moleculareventsincervical cancer. Medicina 55:384. https://doi.org/10.3390/MEDICINA55070384 https://doi.org/10.3390/medicina55070384
  84. PetcaA,BorislavschiA,ZvancaM,etal(2020) Non-sexualHPVtransmission. ExpTherMed 20:1.https://doi.org/10.3892/ETM.2020.9316 https://doi.org/10.3892/etm.2020.9316
  85. ZamaniS,SohrabiA,HosseiniSM,etal(2018) miR-21andmiR-29aderegulationincervical cancer. MicroRNA 8:110–115. https://doi.or g/10.2174/2211536607666181017124349 https://doi.org/10.2174/2211536607666181017124349
  86. SadriNahandJ,MoghoofeiM,SalmaninejadA, etal(2020)ExosomesandmicroRNAsin HPV-mediatedinflammation. IntJCancer 146:305–320. https://doi.org/10.1002/IJC.32688 https://doi.org/10.1002/ijc.32688
  87. LiuM,WangW,ChenH,etal(2020)miRNA expressioninHPV-infectedcervicalcancer. BiomedResInt 2020:2474235. https://doi.org/10.1155/2020/2474235 https://doi.org/10.1155/2020/2474235
  88. LiN,CuiT,GuoW,etal(2019)miR-155-5pand cervicalcancermetastasis. OncoTargetsTher 12:3181–3196. https://doi.org/10.2147/OTT.S193097 https://doi.org/10.2147/ott.s193097
  89. YiY,LiuY,WuW,etal(2018)miR-106b-5pin cervicalcancer. CellDeathDiscov 4:1–15. https://doi.org/10.1038/S41420-018-0096-8 https://doi.org/10.1038/s41420-018-0096-8
  90. LuW,WanX,TaoL,WanJ(2020)lncRNAHULC andmiR-218incervicalcancer. OncoTargets Ther 13:1109–1118. https://doi.org/10.2147/OTT.S232914 https://doi.org/10.2147/ott.s232914
  91. BarmonD,SarmaA,BaruahU,etal(2024) CytologyandriskfactorsinwomenofAssam. medRxiv. https://doi.org/10.1101/2023.01.16.23284644 https://doi.org/10.1101/2023.01.16.23284644
  92. OkerosiS,MokohLW,RubagumyaF,etal(2023) HPV-associatedheadandneckcancersinAfrica. JCOGlobOncol. https://doi.org/10.1200/GO.22.00259 https://doi.org/10.1200/go.22.00259
  93. SchrankTP,PrinceAC,SatheT,etal(2022) NF-kBactivationinHPVcancers. Oncotarget 13:707. https://doi.org/10.18632/ONCOTARGET.28232 https://doi.org/10.18632/oncotarget.28232
  94. SinghNK,AwasthiP,GuptaA,etal(2025) MolecularmechanismsofOSCCpathogenesis. DiscoverApplSci 7:1–17. https://doi.org/10.1007/S42452-024-06260-Y https://doi.org/10.1007/s42452-024-06260-y
  95. KiraveP,GondaliyaP,KulkarniB,etal(2020) miR-155andchemoresistanceinoralcancer. Oncotarget 11:1157. https://doi.org/10.18632/ONCOTARGET.27531 https://doi.org/10.18632/oncotarget.27531
  96. SantosJMO,daSilvaSP,CostaNR,etal(2018) MicroRNAsinHPVmetastasis. Cancers 10:493. https://doi.org/10.3390/CANCERS10120493 https://doi.org/10.3390/cancers10120493
  97. SinghNK,AwasthiP,GuptaA,etal(2025) Environmentalhazardsandchemoresistance. Biology 14:1174. https://doi.org/10.3390/biology14091174 https://doi.org/10.3390/biology14091174
  98. WangW,LiuZ,ZhangX,etal(2020)miR-211-5p inbladdercancer. JGeneMed 22:e3270. https://doi.org/10.1002/JGM.3270 https://doi.org/10.1002/jgm.3270
  99. HuC,WallaceN(2022)BetaHPVandDNArepair deregulation. Viruses 14:948. https://doi.org/10.3390/V14050948 https://doi.org/10.3390/v14050948
  100. ShengS,SuW,MaoD,etal(2022)miR-21and cisplatinresistance. PLoSOne 17:e0267017. https://doi.org/10.1371/JOURNAL.PONE.0267017 https://doi.org/10.1371/journal.pone.0267017
  101. ChapmanBV,WaldAI,AkhtarP,etal(2015) MicroRNA-363targetsmyosin1Btoreduce cellularmigrationinheadandneckcancer. BMC Cancer 15:1–10. https://doi.org/10.1186/S12885-015-1888-3 https://doi.org/10.1186/s12885-015-1888-3
  102. KulkarniA,DograN,ZigrasT(2022)Innovations inthemanagementofvaginalcancer. CurrOncol 29:3082–3092. https://doi.org/10.3390/CURRONCOL29050250 https://doi.org/10.3390/curroncol29050250
  103. GardellaB,GrittiA,SoleymaninejadianE,etal (2022)Newperspectivesintherapeuticvaccines forHPV. Medicina 58:860. https://doi.org/10.3390/MEDICINA58070860 https://doi.org/10.3390/medicina58070860
  104. ChengL,KaźmierczakD,NorenhagJ,etal(2021) MicroRNAgenepanelpredictsvaginal microbiotacomposition. mSystems 6. https://doi.org/10.1128/MSYSTEMS.00175-21 https://doi.org/10.1128/msystems.00175-21
  105. LinC,FranceschiS,CliffordGM(2018)HPVtypes andcancerintheanus:systematicreviewand meta-analysis. LancetInfectDis 18:198–206. https://doi.org/10.1016/S1473-3099(17)30653-9 https://doi.org/10.1016/s1473-3099(17)30653-9
  106. AlbuquerqueA,RiosE,SchmittF(2019)Anal cytologyforcancerscreening:systematic review. Cancers 11:1942. https://doi.org/10.3390/CANCERS11121942 https://doi.org/10.3390/cancers11121942
  107. NowakRG,SchumakerLM,AmbulosNP,etal (2020)MultipleHPVinfectionsinmen undergoingscreening. PapillomavirusRes 10:100200. https://doi.org/10.1016/J.PVR.2020.100200 https://doi.org/10.1016/j.pvr.2020.100200
  108. BitarSA,BallouzT,DoughanS,etal(2021) MicroRNAsinanalcancerscreening. WorldJ GastrointestPathophysiol 12:59. https://doi.org/10.4291/WJGP.V12.I4.59 https://doi.org/10.4291/wjgp.v12.i4.59
  109. RasmussenCL,ThomsenLT,BaandrupL,etal (2023)TrendsinHPV/p16positivityinvulvar cancer. IntJCancer 152:2424–2432. https://doi.org/10.1002/IJC.34446 https://doi.org/10.1002/ijc.34446
  110. SinghN,GilksCB(2020)Vulvalsquamouscell carcinomaandprecursors. Histopathology 76:128–138.https://doi.org/10.1111/HIS.13989 https://doi.org/10.1111/his.13989
  111. AlloG,YapML,CuarteroJ,etal(2020) HPV-independentvulvarcarcinomaprognosis. IntJGynecolPathol 39:391–399. https://doi.org/10.1097/PGP.0000000000000620 https://doi.org/10.1097/pgp.0000000000000620
  112. BarwalTS,SinghN,SharmaU,etal(2022) miR-590-5pinoncogenesis. CancerTreatRes Commun 32:100593. https://doi.org/10.1016/J.CTARC.2022.100593 https://doi.org/10.1016/j.ctarc.2022.100593
  113. YangXH,GuoF(2018)miR-3147asoncomiRin vulvarcancer. MolMedRep 17:6397–6404. https://doi.org/10.3892/MMR.2018.8697 https://doi.org/10.3892/mmr.2018.8697
  114. YangS,ZhaoY,WangL,etal(2019)miR-4712-5p promotesvulvarcarcinomaproliferationvia PTEN. OncolRep 42:1689–1698. https://doi.org/10.3892/OR.2019.7320 https://doi.org/10.3892/or.2019.7320
  115. AhmedME,KhalilMI,KamelMH,etal(2021) Managementofpenilecancer. CurrTreat OptionsOncol 22:1–13. https://doi.org/10.1007/S11864-020-00802-3 https://doi.org/10.1007/s11864-020-00802-3
  116. AminiAP,BrookesTS,ShahH,etal(2023)Penile cancerandHIVinfection. IntJSTDAIDS 34:214–228. https://doi.org/10.1177/09564624221148622 https://doi.org/10.1177/09564624221148622
  117. ShaoY,HuX,RenS,etal(2022)Surgical strategiesinpenilecancer. SciRep 12:1–9. https://doi.org/10.1038/S41598-022-06494-Z daSilvaJ,daCostaCC,deFariasRamosI,etal (2022)miRNAsinHPV-associatedpenilecancer. FrontGenet 13:875939. https://doi.org/10.3389/FGENE.2022.875939 https://doi.org/10.1038/s41598-022-06494-z
  118. AyoubianH,HeinzelmannJ,HöltersS,etal (2021)miRNAexpressioninpenilecarcinoma. Cancers 13:1480. https://doi.org/10.3390/CANCERS13061480 https://doi.org/10.3390/cancers13061480
  119. BarzonL,CappellessoR,PetaE,etal(2014) HPV-relatedmiRNAsinpenilecarcinoma. AmJ Pathol 184:3376–3383. https://doi.org/10.1016/J.AJPATH.2014.08.004 https://doi.org/10.1016/j.ajpath.2014.08.004
  120. PinhoJD,SilvaGEB,JúniorAALT,etal(2020) miRNAsasbiomarkersinpenilecancer. Asian PacJCancerPrev 21:391. https://doi.org/10.31557/APJCP.2020.21.2.391 https://doi.org/10.31557/apjcp.2020.21.2.391
  121. KuasneH,Barros-FilhoMC,Busso-LopesA,etal (2017)IntegrativemiRNAandmRNAanalysisin penilecancer. Oncotarget 8:15294. https://doi.org/10.18632/ONCOTARGET.14783 https://doi.org/10.18632/oncotarget.14783
  122. BruniL,Saura-LázaroA,MontoliuA,etal(2021) HPVvaccinationworldwidecoverage. PrevMed 144:106399. https://doi.org/10.1016/J.YPMED.2020.106399 https://doi.org/10.1016/j.ypmed.2020.106399
  123. GarbugliaAR,LapaD,SiasC,etal(2020) TherapeuticandprophylacticHPVvaccines. FrontImmunol 11:503743. https://doi.org/10.3389/FIMMU.2020.00188 https://doi.org/10.3389/fimmu.2020.00188
  124. ReuschenbachM,DoorbarJ,delPinoM,etal (2023)HPVvaccinesincancerpatients. Vaccine 41:6194–6205. https://doi.org/10.1016/J.VACCINE.2023.08.047 https://doi.org/10.1016/j.vaccine.2023.08.047
  125. YanF,CowellLG,TomkiesA,DayAT(2023) TherapeuticvaccinationforHPV-mediated cancers. CurrOtorhinolaryngolRep 11:44–61. https://doi.org/10.1007/S40136-023-00443-8 https://doi.org/10.1007/s40136-023-00443-8
  126. ZhouJZ,JouJ,CohenE(2021)Vaccine strategiesforHPV-associatedheadandneck cancers. Cancers 14:33. https://doi.org/10.3390/CANCERS14010033 https://doi.org/10.3390/cancers14010033
  127. MoY,MaJ,ZhangH,etal(2022)Prophylactic andtherapeuticHPVvaccines. FrontCellInfect Microbiol 12:909223. https://doi.org/10.3389/FCIMB.2022.909223 https://doi.org/10.3389/fcimb.2022.909223
  128. AkhatovaA,ChanCK,AzizanA,Aimagambetova G(2021)TherapeuticDNAvaccinesforcervical cancer. Vaccines 10:53. https://doi.org/10.3390/VACCINES10010053 https://doi.org/10.3390/vaccines10010053
  129. FirdausFZ,BartlettS,HusseinWM,etal(2023) Liposomaltherapeuticvaccinesforcervical cancer. Pharmaceutics 15:602. https://doi. org/10.3390/PHARMACEUTICS15020602 https://doi.org/10.3390/pharmaceutics15020602
  130. MousaviT,SattariSaraviS,ValadanR,etal (2020)AdjuvantsinHPVvaccines:asystematic review. ArchVirol 165:263–284. https://doi.org/10.1007/S00705-019-04479-4 https://doi.org/10.1007/s00705-019-04479-4
  131. CoffmanRL,SherA,SederRA(2010)Vaccine adjuvantsandinnateimmunity. Immunity 33:492–503. https://doi.org/10.1016/J.IMMUNI.2010.10.002 https://doi.org/10.1016/j.immuni.2010.10.002
  132. GhoshS,ShahPA,JohnsonFM(2022) Immunotherapyandtargetedtherapyinhead andneckcancer. IntJMolSci 23:7889. https://doi.org/10.3390/IJMS23147889 https://doi.org/10.3390/ijms23147889
  133. MortezaeeK(2020)Immuneescapeinsolid tumors. LifeSci 258:118110. https://doi.org/10.1016/J.LFS.2020.118110 https://doi.org/10.1016/j.lfs.2020.118110
  134. FerrallL,LinKY,RodenRBS,etal(2021)Cervical cancerimmunotherapy. ClinCancerRes 27:4953–4973. https://doi.org/10.1158/1078-0432.CCR-20-2833 https://doi.org/10.1158/1078-0432.ccr-20-2833
  135. ShamseddineAA,BurmanB,LeeNY,etal(2021) TumorimmunityinHPV-relatedcancers. Cancer Discov 11:1896–1912. https://doi.org/10.1158/2159-8290.CD-20-1760 https://doi.org/10.1158/2159-8290.cd-20-1760
  136. Gutiérrez-HoyaA,Soto-CruzI(2021)NKcell regulationincervicalcancer. Cells 10:3104. https://doi.org/10.3390/CELLS10113104 https://doi.org/10.3390/cells10113104
  137. XiaC,HeZ,CaiY,LiangS(2020)PI3K/Akt pathwayandNKcellactivity. EurJPharmacol 875:173057. https://doi.org/10.1016/J.EJPHAR.2020.173057 https://doi.org/10.1016/j.ejphar.2020.173057
  138. BagchiS,YuanR,EnglemanEG(2021)Immune checkpointinhibitorsincancertherapy. Annu RevPathol 16:223–249. https://doi.org/10.1146/ANNUREV-PATHOL-042020-042741 https://doi.org/10.1146/annurev-pathol-042020-042741
  139. StevanovićS,DraperLM,LanghanMM,etal (2015)Regressionofmetastaticcervicalcancer usingTcells. JClinOncol 33:1543–1550. https://doi.org/10.1200/JCO.2014.58.9093 https://doi.org/10.1200/jco.2014.58.9093
  140. RoofL,YilmazE(2023)Immunotherapyin HPV-relatedoropharyngealcancer. CurrTreat OptionsOncol 24:170–183. https://doi.org/10.1007/S11864-023-01050-X https://doi.org/10.1007/s11864-023-01050-x
  141. StevanovićS,PasettoA,HelmanSR,etal(2017) ImmunogenictumorantigensinHPVcancers. Science 356:200–205. https://doi.org/10.1126/SCIENCE.AAK9510 https://doi.org/10.1126/science.aak9510
  142. StevanovicS,HelmanSR,WunderlichJR,etal (2019)Tumor-infiltratinglymphocytetherapyin HPVcancers. ClinCancerRes 25:1486–1493. https://doi.org/10.1158/1078-0432.CCR-18-2722 https://doi.org/10.1158/1078-0432.ccr-18-2722
  143. DoranSL,StevanovićS,AdhikaryS,etal(2019) T-cellreceptorgenetherapyforHPVcancers. J ClinOncol 37:2759–2768. https://doi.org/10.1200/JCO.18.02424 https://doi.org/10.1200/jco.18.02424
  144. PapaS,AdamiA,MetoudiM,etal(2018)CAR T-cellimmunotherapyinheadandneckcancer. JClinOncol 36:3046. https://doi.org/10.1200/JCO.2018.36.15SUPPL.3046 https://doi.org/10.1200/jco.2018.36.15suppl.3046
  145. OkuM,IshinoR,UchidaS,etal(2021)Oncolytic HSV-1therapy. BrJHaematol 192:343–353. https://doi.org/10.1111/BJH.17173 https://doi.org/10.1111/bjh.17173
  146. AntoniouE,OrovouE,SarellaA,etal(2020)Zika virusandmicrocephaly. IntJEnvironResPublic Health 17:3806. https://doi.org/10.3390/IJERPH17113806 https://doi.org/10.3390/ijerph17113806
  147. FerreiraRO,GranhaI,FerreiraRS,etal(2021) OncolyticZikavirusintumors. Viruses 13:2103. https://doi.org/10.3390/V13102103 https://doi.org/10.3390/v13102103
  148. NairS,MazzoccoliL,JashA,etal(2021)Zika virusandcancerimmunotherapy. JCIInsight 6:e144619. https://doi.org/10.1172/JCI.INSIGHT.144619 https://doi.org/10.1172/jci.insight.144619
  149. AndtbackaRHI,KaufmanHL,CollichioF,etal (2015)Talimogenelaherparepvecinmelanoma. JClinOncol 33:2780–2788. https://doi.org/10.1200/JCO.2014.58.3377 https://doi.org/10.1200/jco.2014.58.3377
  150. KellyH,WeissHA,BenaventeY,etal(2018)ART andHPV-relatedcancerrisk. LancetHIV 5:e45–e58. https://doi.org/10.1016/S2352-3018(17)30149-2 https://doi.org/10.1016/s2352-3018(17)30149-2